Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis

Table 1

Characteristics of studies for systematic review and meta-analysis.

Number	First author	Jadad score	Concurrent therapy	Augmentation; (mg/day, daily max. dose)	Duration (weeks)	(drop)	Primary outcome		Secondary outcome
1	Fleischhacker (2010) [8]	4	Clozapine	Aripiprazole (15); placebo	16	108 (0); 99 (0)	BWT	<0.001	PANSS	0.37
2	Narula (2010) [9]	3	Olanzapine	Topiramate (100); placebo	12	33 (3); 34 (2)	BMI	0.004	PANSS	0.00
3	Afshar (2009) [10]	4	Clozapine	Topiramate (300); placebo	8	16 (0); 16 (0)	BMI	≤0.05	PANSS	<0.001
4	Baptista (2008) [11]	4	Olanzapine	Metformin (1700) + sibutramine (20); placebo	12	13 (0); 15 (0)	BWT	0.19	BPRS	0.15
5	Wu (2008) [12]	5	Olanzapine	Metformin (750); placebo	12	20 (2); 20 (1)	BWT	<0.02	SAPS	0.52
6	Baptista (2007) [13]	4	Olanzapine	Metformin (2250); placebo	12	40 (4); 40 (4)	BWT	0.09	BPRS	ns
7	Henderson (2007) [14]	5	Clozapine	Sibutramine (15); placebo	12	10 (0); 11 (3)	BWT	0.31	PANSS	0.96
8	Poyurovsky (2007) [15]	5	Olanzapine	Reboxetine (4); placebo	6	31 (9); 28 (9)	BWT	0.013	SAPS	0.96
9	Baptista (2006) [16]	4	Olanzapine	Metformin (1700); placebo	14	20 (1); 20 (2)	BWT	0.4	BPRS	ns
10	Henderson (2005) [7]	4	Olanzapine	Sibutramine (15); placebo	12	19 (3); 18 (3)	BWT	0.009	PANSS	ns
11	Poyurovsky (2004) [17]	3	Olanzapine	Famotidine (40); placebo	6	7 (0); 7 (0)	BWT	0.91	SAPS	0.54
12	Cavazzoni (2003) [18]	2	Olanzapine	Nizatidine (300); placebo	16	57 (0); 60 (0)	BWT	0.36	BPRS	0.63
13	Poyurovsky (2003) [19]	3	Olanzapine	Reboxetine (4); placebo	6	13 (3); 13 (3)	BWT	0.03	SAPS	0.83
14	Poyurovsky (2002) [20]	3	Olanzapine	Fluoxetine (20); placebo	8	15 (4); 15 (2)	BWT	0.44	SAPS	0.83